Disease Pathways and Clinical Concepts
A directory for fatty liver disease, metabolic syndrome, diabetes, cardiovascular risk, uric acid, inflammation, kidney disease, and related systems.
Overview5 links
Fatty liver and liver metabolism6 links
Insulin resistance and metabolic syndrome11 links
- Diabetes and Cancer
- Metabolic Syndrome Biochemistry
- Metabolic Syndrome Clinical Aspects
- Metabolic Syndrome: Criteria for Diagnosis
- Obesity
- Prediabetes
- Type 2 Diabetes
- Visceral Adiposity and Inflammatory Signaling
- What Is Metabolic Syndrome?
- Why Some Populations Develop Diabetes at Lower Body Weight
- Why Some Populations Get Diabetes at Lower BMI
Cardiovascular risk8 links
Uric acid, kidney, and blood pressure6 links
Related disease systems6 links
Patient Explainers
Plain-language entry points for readers trying to recognize early metabolic disease and inherited risk.
2026 Evidence Update
Summary: The metabolic disease section should now explicitly connect liver, adipose tissue, pancreas, cardiovascular risk, and kidney risk. The 2026 AHA/ACC/ADA/ASN cardiovascular-kidney-metabolic guideline formalizes this integrated view through CKM syndrome: metabolic risk factors such as obesity and type 2 diabetes intersect with chronic kidney disease and cardiovascular disease rather than sitting in separate silos.
This matters for Internets because fructose biology, fatty liver, hyperuricemia, triglycerides, hypertension, kidney disease, and cardiovascular disease are often different surfaces of the same underlying metabolic network. The newer guideline framing supports the site’s section architecture: readers should be able to move from insulin resistance and MASLD to dyslipidemia, hypertension, CKD, HFpEF, and cardiovascular disease without treating each page as a disconnected topic.
Sources: 2026 AHA/ACC/ADA/ASN CKM guideline summary, JACC Guideline-at-a-Glance; American Heart Association, CKM guideline news release.
Related Framework
For the current integrated guideline framework connecting metabolic disease with kidney and cardiovascular risk, see Cardiovascular-Kidney-Metabolic Syndrome.
New Clinical Marker Pages
For deeper clinical orientation, see MASLD screening with FIB-4 and liver stiffness, albuminuria and eGFR for kidney risk, and ApoB and non-HDL cholesterol for atherogenic dyslipidemia.
Related Treatment Pages
For current therapy context, see GLP-1 and GIP therapy, SGLT2 inhibitors for kidney and heart protection, and MASH treatment with resmetirom and metabolic care.